Mirdamadi Ahmad, Abrishamkar Rana, Kargaran Afrooz
Associate Professor, Department of Cardiology, Najafabad Branch, Islamic Azad University, Isfahan, Iran.
Medical Practitioner, Najafabad Branch, Islamic Azad University, Isfahan, Iran.
ARYA Atheroscler. 2022 Jan;18(1):1-6. doi: 10.48305/arya.v18i1.2146.
Hypertension (HTN) is the second leading risk factor for death and disability. One fourth of healthcare in Eastern Europe and Central Asia is being spent on blood pressure (BP)-related diseases. An important situation in patients with high BP is hypertensive crisis (BP > 180/120 mmHg), which is divided to hypertensive emergency and urgency. Therefore, here, we decided to compare the effect of captopril and clonidine in patients with hypertensive urgencies, and their side effects.
This was a parallel-group randomized clinical trial. Patients, who referred to emergency ward with any symptoms of hypertensive crisis, underwent a careful history taking and clinical examination. Individuals with systolic BP (SBP) ≥ 180 mmHg or diastolic BP (DBP) ≥ 110 mmHg with no evidence of end organ damage were randomly assigned into two interventions, clonidine and captopril. 25% decrease in BP was considered as ideal relief.
Regarding the duration of response to treatment drugs, patients who received clonidine relieved significantly faster than those who received captopril (P = 0.016). Moreover, the frequencies of side effects such as headache, dizziness/vertigo, dry mouth, and drowsiness in the clonidine group were significantly lower than captopril group (P < 0.05).
Patients in clonidine group relieved sooner and experienced fewer side effects. Therefore, this study suggests clonidine as a more effective therapeutic for hypertensive urgency compared with captopril.
高血压(HTN)是导致死亡和残疾的第二大风险因素。东欧和中亚地区四分之一的医疗保健支出用于治疗与血压(BP)相关的疾病。高血压患者的一种重要情况是高血压危象(血压>180/120 mmHg),可分为高血压急症和亚急症。因此,我们决定比较卡托普利和可乐定对高血压亚急症患者的疗效及其副作用。
这是一项平行组随机临床试验。因任何高血压危象症状转诊至急诊病房的患者,均接受了详细的病史采集和临床检查。收缩压(SBP)≥180 mmHg或舒张压(DBP)≥110 mmHg且无终末器官损害证据的患者被随机分为两组进行干预,即可乐定组和卡托普利组。血压下降25%被视为理想的缓解效果。
在治疗药物的反应持续时间方面,接受可乐定治疗的患者缓解速度明显快于接受卡托普利治疗的患者(P = 0.016)。此外,可乐定组头痛、头晕/眩晕、口干和嗜睡等副作用的发生率明显低于卡托普利组(P < 0.05)。
可乐定组患者缓解更快,副作用更少。因此,本研究表明,与卡托普利相比,可乐定是治疗高血压亚急症更有效的药物。